{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:18:16Z","timestamp":1783502296494,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The efficacy of cancer treatments has links to the intestinal microbiome. Mucositis is a dose-limiting intestinal pro-inflammatory side effect of cancer treatments,  that increases the risk of diarrhoea, mucositis, and in severe cases, febrile neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effect of cancer treatments on Quality of Life (QoL) was assessed using the FACT C questionnaire that included patient wellbeing and gut adverse symptoms (e.g. diarrhoea). Participants rated faecal samples via the Bristol Stool Chart. In addition, bacterial DNA was extracted from faecal samples, sequenced, and taxonomically examined. The incidence \/ severity of neutropenia was assessed with white blood cell and neutrophil counts. Circulating SCFAs and plasma lipopolysaccharide (LPS) endotoxin levels were recorded and correlated to intestinal mucositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Improvement in bowel function, with reduction in constipation and or diarrhoea or absence of significant disturbance to bowel function was recorded in 85% of the participants. One participant developed febrile neutropenia and two developed bowel toxicity during the study, that was unrelated to the test formulation. No significant changes in microbiota alpha- and beta-diversity at the phylum and species levels respectively from baseline to end of study treatment was observed. None of the participants had raised plasma-endotoxin levels from baseline to the first and subsequent treatment cycles for their cancers. Probiotics in this cohort were deemed safe and tolerable. Significant improvement in emotional QoL scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015) was reported with increased number of chemotherapy cycles. In a related observational study of exceptional responders to chemotherapy, participants were found to have had a high intake of fruits, vegetables, and fibre possibly indicative of a more balanced intestinal microbiota.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A multi-strain probiotic formulation was safe and tolerated in this chronically ill cohort that were undergoing oncological treatment. The probiotic formulation alleviated diarrhoea, constipation and maintained stool consistency\/frequency during the multiple treatments with chemotherapy and radiotherapy. Intestinal dysbiosis that is\u00a0characterised by decreased microbial diversity and increased pro-inflammatory species was not observed. Probiotic supplementation may have helped reduce dysbiosis during cancer treatments. These improvements may have been critical with the observation that emotional wellbeing was significantly improved from baseline. Hence albeit that the study had limitations, the probiotic intervention provided adjunctive treatment support to the patients. What is of scientifically plausible interest is that probiotics have a long association historically with human hosts and as such ratify their inclusion offering a significant adjunctive therapeutic potential. Future studies warrant larger sample sizes, control groups and should limit recruitment to a largely homogenous group of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10787-024-01503-1","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T16:11:50Z","timestamp":1719418310000},"page":"2317-2335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An exploratory study of a multi-species probiotic formulation and markers of health in a real-world oncological cohort in the time of covid"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1446-8221","authenticated-orcid":false,"given":"Michael","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-426X","authenticated-orcid":false,"given":"Ravichandra","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2737-2264","authenticated-orcid":false,"given":"Flavia","family":"Huygens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-1222","authenticated-orcid":false,"given":"Stephen","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7490-9298","authenticated-orcid":false,"given":"Luis","family":"Vitetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"1","key":"1503_CR1","doi-asserted-by":"publisher","first-page":"188494","DOI":"10.1016\/j.bbcan.2020.188494","volume":"1875","author":"A Badgeley","year":"2021","unstructured":"Badgeley A, Anwar H, Modi K, Murphy P, Lakshmikuttyamma A (2021) Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives. Biochim Biophys Acta Rev Cancer 1875(1):188494. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188494","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"1503_CR2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1080\/1040841X.2022.2035313","volume":"48","author":"SA Bhat","year":"2022","unstructured":"Bhat SA, Kaur R, Chauhan A, Pal A (2022) The microbiome and precision oncology: an emerging paradigm in anticancer therapy. Crit Rev Microbiol 48(6):770\u2013783. https:\/\/doi.org\/10.1080\/1040841X.2022.2035313","journal-title":"Crit Rev Microbiol"},{"issue":"Suppl 1","key":"1503_CR3","doi-asserted-by":"publisher","first-page":"394s","DOI":"10.3945\/ajcn.113.071357","volume":"100","author":"KE Bradbury","year":"2014","unstructured":"Bradbury KE, Appleby PN, Key TJ (2014) Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr 100(Suppl 1):394s-s398. https:\/\/doi.org\/10.3945\/ajcn.113.071357","journal-title":"Am J Clin Nutr"},{"key":"1503_CR4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3389\/fmicb.2018.00736","volume":"9","author":"SI Cazorla","year":"2018","unstructured":"Cazorla SI, Maldonado-Galdeano C, Weill R, De Paula J, Perdig\u00f3n GDV (2018) Oral administration of probiotics increases paneth cells and intestinal antimicrobial activity. Front Microbiol 9:736. https:\/\/doi.org\/10.3389\/fmicb.2018.00736","journal-title":"Front Microbiol"},{"issue":"3","key":"1503_CR5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570\u2013579. https:\/\/doi.org\/10.1200\/JCO.1993.11.3.570","journal-title":"J Clin Oncol"},{"key":"1503_CR6","doi-asserted-by":"publisher","first-page":"568457","DOI":"10.3389\/fmicb.2020.568457","volume":"11","author":"M Chen","year":"2020","unstructured":"Chen M, Liu S, Imam K, Sun L, Wang Y, Gu T et al (2020) The Effect of Xylooligosaccharide, Xylan, and Whole Wheat Bran on the Human Gut Bacteria. Front Microbiol 11:568457. https:\/\/doi.org\/10.3389\/fmicb.2020.568457","journal-title":"Front Microbiol"},{"issue":"3","key":"1503_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41596-019-0264-1","volume":"15","author":"J Chong","year":"2020","unstructured":"Chong J, Liu P, Zhou G, Xia J (2020) Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data. Nat Protoc 15(3):799\u2013821. https:\/\/doi.org\/10.1038\/s41596-019-0264-1","journal-title":"Nat Protoc"},{"issue":"7402","key":"1503_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11209","volume":"486","author":"HMP","year":"2012","unstructured":"Consortium, HMP (2012) A framework for human microbiome research. Nature 486(7402):215\u2013221. https:\/\/doi.org\/10.1038\/nature11209","journal-title":"Nature"},{"key":"1503_CR9","doi-asserted-by":"publisher","first-page":"153473542211443","DOI":"10.1177\/15347354221144309","volume":"21","author":"R Danis","year":"2022","unstructured":"Danis R, Mego M, Antonova M, Stepanova R, Svobodnik A, Hejnova R et al (2022) Orally administered probiotics in the prevention of chemotherapy (\u00b1 Radiotherapy)-induced gastrointestinal toxicity: a systematic review with meta-analysis of randomized trials. Integr Cancer Ther 21:15347354221144308. https:\/\/doi.org\/10.1177\/15347354221144309","journal-title":"Integr Cancer Ther"},{"issue":"Suppl 1","key":"1503_CR10","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1073\/pnas.1000087107","volume":"108","author":"L Dethlefsen","year":"2011","unstructured":"Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108(Suppl 1):4554\u20134561. https:\/\/doi.org\/10.1073\/pnas.1000087107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"W1","key":"1503_CR11","doi-asserted-by":"publisher","first-page":"W180","DOI":"10.1093\/nar\/gkx295","volume":"45","author":"A Dhariwal","year":"2017","unstructured":"Dhariwal A, Chong J, Habib S, King IL, Agellon LB, Xia J (2017) MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. Nucleic Acids Res 45(W1):W180\u2013W188. https:\/\/doi.org\/10.1093\/nar\/gkx295","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"1503_CR12","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/jssc.201101121","volume":"35","author":"R Garcia-Villalba","year":"2012","unstructured":"Garcia-Villalba R, Gimenez-Bastida JA, Garcia-Conesa MT, Tomas-Barberan FA, Carlos Espin J, Larrosa M (2012) Alternative method for gas chromatography-mass spectrometry analysis of short-chain fatty acids in faecal samples. J Sep Sci 35(15):1906\u20131913. https:\/\/doi.org\/10.1002\/jssc.201101121","journal-title":"J Sep Sci"},{"issue":"3","key":"1503_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12915","volume":"29","author":"VJ Gonz\u00e1lez-Mercado","year":"2020","unstructured":"Gonz\u00e1lez-Mercado VJ, Sarkar A, Penedo FJ, P\u00e9rez-Santiago J, Mcmillan S, Marrero SJ et al (2020) Gut microbiota perturbation is associated with acute sleep disturbance among rectal cancer patients. J Sleep Res 29(3):e12915. https:\/\/doi.org\/10.1111\/jsr.12915","journal-title":"J Sleep Res"},{"issue":"5","key":"1503_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"1","key":"1503_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40168-020-00811-2","volume":"8","author":"Y Heshiki","year":"2020","unstructured":"Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L et al (2020) Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome 8(1):28. https:\/\/doi.org\/10.1186\/s40168-020-00811-2","journal-title":"Microbiome"},{"issue":"Pt B","key":"1503_CR16","first-page":"1","volume":"100","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2012","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2012) Biological agents. IARC Monogr Eval Carcinog Risks Hum 100(Pt B):1\u2013441","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"issue":"10","key":"1503_CR17","doi-asserted-by":"publisher","first-page":"11595","DOI":"10.1096\/fj.201901327R","volume":"33","author":"O Juanola","year":"2019","unstructured":"Juanola O, Ferrusquia-Acosta J, Garcia-Villalba R, Zapater P, Magaz M, Marin A et al (2019) Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. Faseb j 33(10):11595\u201311605. https:\/\/doi.org\/10.1096\/fj.201901327R","journal-title":"Faseb j"},{"key":"1503_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2019.01.015","volume":"447","author":"W Li","year":"2019","unstructured":"Li W, Deng Y, Chu Q, Zhang P (2019) Gut microbiome and cancer immunotherapy. Cancer Lett 447:41\u201347. https:\/\/doi.org\/10.1016\/j.canlet.2019.01.015","journal-title":"Cancer Lett"},{"issue":"1","key":"1503_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13014-020-01735-9","volume":"16","author":"J Liu","year":"2021","unstructured":"Liu J, Liu C, Yue J (2021) Radiotherapy and the gut microbiome: facts and fiction. Radiat Oncol 16(1):9. https:\/\/doi.org\/10.1186\/s13014-020-01735-9","journal-title":"Radiat Oncol"},{"issue":"5","key":"1503_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/apt.13302","volume":"42","author":"E Montassier","year":"2015","unstructured":"Montassier E, Gastinne T, Vangay P, Al-Ghalith GA, Varannes BD, Massart S et al (2015) Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 42(5):515\u2013528. https:\/\/doi.org\/10.1111\/apt.13302","journal-title":"Aliment Pharmacol Ther"},{"issue":"21","key":"1503_CR21","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1093\/bioinformatics\/btu494","volume":"30","author":"DH Parks","year":"2014","unstructured":"Parks DH, Tyson GW, Hugenholtz P, Beiko RG (2014) STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics 30(21):3123\u20133124. https:\/\/doi.org\/10.1093\/bioinformatics\/btu494","journal-title":"Bioinformatics"},{"issue":"3","key":"1503_CR22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jpainsymman.2017.11.009","volume":"55","author":"PE Perez-Cruz","year":"2018","unstructured":"Perez-Cruz PE, Shamieh O, Paiva CE, Kwon JH, Muckaden MA, Bruera E et al (2018) Factors associated with attrition in a multicenter longitudinal observational study of patients with advanced cancer. J Pain Symptom Manage 55(3):938\u2013945. https:\/\/doi.org\/10.1016\/j.jpainsymman.2017.11.009","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"1503_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2022-328166","volume":"72","author":"N Proch\u00e1zkov\u00e1","year":"2023","unstructured":"Proch\u00e1zkov\u00e1 N, Falony G, Dragsted LO, Licht TR, Raes J, Roager HM (2023) Advancing human gut microbiota research by considering gut transit time. Gut 72(1):180\u2013191. https:\/\/doi.org\/10.1136\/gutjnl-2022-328166","journal-title":"Gut"},{"issue":"11","key":"1503_CR24","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1080\/10408398.2020.1765310","volume":"61","author":"AH Rad","year":"2021","unstructured":"Rad AH, Aghebati-Maleki L, Kafil HS, Abbasi A (2021) Molecular mechanisms of postbiotics in colorectal cancer prevention and treatment. Crit Rev Food Sci Nutr 61(11):1787\u20131803. https:\/\/doi.org\/10.1080\/10408398.2020.1765310","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"5","key":"1503_CR25","doi-asserted-by":"publisher","first-page":"G712","DOI":"10.1152\/ajpgi.00380.2020","volume":"320","author":"AT Sougiannis","year":"2021","unstructured":"Sougiannis AT, Vanderveen BN, Davis JM, Fan D, Murphy EA (2021) Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiol Gastrointest Liver Physiol 320(5):G712-g719. https:\/\/doi.org\/10.1152\/ajpgi.00380.2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"1503_CR26","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1002\/cphy.c210052","volume":"13","author":"J Sun","year":"2023","unstructured":"Sun J, Xia Y (2023) Microbiome in Colonic Carcinogenesis. Compr Physiol 13(3):4685\u20134708. https:\/\/doi.org\/10.1002\/cphy.c210052","journal-title":"Compr Physiol"},{"key":"1503_CR27","unstructured":"Thermo-Fisher-Scientific 2021. Thermo Scientific Instructions: Pierce LAL Chromogenic Endotoxin Quantitation Kit. Number 88282."},{"key":"1503_CR28","unstructured":"Thermofisher-Scientific. 2021. ThermoFisher Scientific. Pierce Chromogenic Endotoxin Quant Kit. Catalog number: A39552 [Online]. Available: https:\/\/www.thermofisher.com\/order\/catalog\/product\/A39552?SID=srch-srp-A39552#\/A39552?SID=srch-srp-A39552 [Accessed]."},{"issue":"4","key":"1503_CR29","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/1534735418794885","volume":"17","author":"M Thomsen","year":"2018","unstructured":"Thomsen M, Vitetta L (2018) Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis. Integr Cancer Ther 17(4):1027\u20131047. https:\/\/doi.org\/10.1177\/1534735418794885","journal-title":"Integr Cancer Ther"},{"issue":"6","key":"1503_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3920\/bm2017.0172","volume":"9","author":"M Thomsen","year":"2018","unstructured":"Thomsen M, Clarke S, Vitetta L (2018) The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. Benef Microbes 9(6):899\u2013916. https:\/\/doi.org\/10.3920\/bm2017.0172","journal-title":"Benef Microbes"},{"issue":"5","key":"1503_CR31","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3390\/microorganisms11051334","volume":"11","author":"L Vitetta","year":"2023","unstructured":"Vitetta L, Bambling M, Strodl E (2023) Probiotics and commensal bacteria metabolites trigger epigenetic changes in the gut and influence beneficial mood dispositions. Microorganisms 11(5):1334. https:\/\/doi.org\/10.3390\/microorganisms11051334","journal-title":"Microorganisms"},{"key":"1503_CR32","doi-asserted-by":"publisher","first-page":"1138362","DOI":"10.3389\/fonc.2023.1138362","volume":"13","author":"X Wang","year":"2023","unstructured":"Wang X, Geng S (2023) Diet-gut microbial interactions influence cancer immunotherapy. Front Oncol 13:1138362. https:\/\/doi.org\/10.3389\/fonc.2023.1138362","journal-title":"Front Oncol"},{"issue":"5","key":"1503_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126312","volume":"10","author":"A Wang","year":"2015","unstructured":"Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C et al (2015) Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS ONE 10(5):e0126312. https:\/\/doi.org\/10.1371\/journal.pone.0126312","journal-title":"PLoS ONE"},{"issue":"Pt B","key":"1503_CR34","first-page":"1","volume":"100","author":"Working-Group-Iarc","year":"2012","unstructured":"Working-Group-Iarc (2012) Biological agents. IARC Monogr Eval Carcinog Risks Hum 100(Pt B):1\u2013441","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"1503_CR35","doi-asserted-by":"publisher","first-page":"153473541987635","DOI":"10.1177\/1534735419876351","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K (2019) Manipulating Gut microbiota composition to enhance the therapeutic effect of cancer immunotherapy. Integr Cancer Ther 18:1534735419876351. https:\/\/doi.org\/10.1177\/1534735419876351","journal-title":"Integr Cancer Ther"},{"key":"1503_CR36","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.2147\/cmar.S328249","volume":"13","author":"H Zhou","year":"2021","unstructured":"Zhou H, Yuan Y, Wang H, Xiang W, Li S, Zheng H et al (2021) Gut microbiota: a potential target for cancer interventions. Cancer Manag Res 13:8281\u20138296. https:\/\/doi.org\/10.2147\/cmar.S328249","journal-title":"Cancer Manag Res"},{"key":"1503_CR37","doi-asserted-by":"publisher","first-page":"877939","DOI":"10.3389\/fimmu.2022.877939","volume":"13","author":"P Zhou","year":"2022","unstructured":"Zhou P, Hu Y, Wang X, Shen L, Liao X, Zhu Y et al (2022) Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy. Front Immunol 13:877939. https:\/\/doi.org\/10.3389\/fimmu.2022.877939","journal-title":"Front Immunol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01503-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01503-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01503-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:50:07Z","timestamp":1783500607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01503-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01503-1","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LV, MT have received competitive grant and commercial funding for research with probiotics and have participated in clinical trials with probiotics. All other remaining authors have no conflict of interest with this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}